Literature DB >> 1378423

Oligodendrocytes lack glycolipid anchored proteins which protect them against complement lysis. Restoration of resistance to lysis by incorporation of CD59.

M G Wing1, J Zajicek, D J Seilly, D A Compston, P J Lachmann.   

Abstract

Rat oligodendrocytes, which activate the classical pathway of complement in the absence of antibody, are highly sensitive in a reactive lysis assay using human C5b6 and EDTA serum. Oligodendrocytes may be relatively deficient in glycolipid-linked complement regulatory protein(s), since digestion with phosphatidylinositol-specific phospholipase C (PI-PLC) failed to increase their sensitivity to serum, whereas complement-insensitive astrocytes, when treated with PI-PLC, became strikingly sensitive. To test the hypothesis that oligodendrocytes lack terminal complement regulatory molecule(s), human erythrocyte CD59, a recently described complement regulatory protein, was purified to homogeneity. The biological activity of the preparation was confirmed by reincorporating the protein into guinea-pig erythrocytes through its glycolipid anchor, which resulted in dose-dependent protection against human C5b6 and EDTA serum. Incorporation of 10(5) molecules of human CD59 into rat oligodendrocytes resulted in good protection against homologous human complement (76%), and significant protection against rat complement homologous to the cell (36%). Protection could be reversed using an antibody to CD59.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1378423      PMCID: PMC1421748     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  29 in total

1.  Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels.

Authors:  L S Zalman; L M Wood; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

2.  Endogenous association of decay-accelerating factor (DAF) with C4b and C3b on cell membranes.

Authors:  T Kinoshita; M E Medof; V Nussenzweig
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

3.  The immunogenesis of the multiple sclerosis plaque.

Authors:  C E Lumsden
Journal:  Brain Res       Date:  1971-05-21       Impact factor: 3.252

4.  Growth of a rat neuroblastoma cell line in serum-free supplemented medium.

Authors:  J E Bottenstein; G H Sato
Journal:  Proc Natl Acad Sci U S A       Date:  1979-01       Impact factor: 11.205

5.  A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium.

Authors:  M C Raff; R H Miller; M Noble
Journal:  Nature       Date:  1983 Jun 2-8       Impact factor: 49.962

6.  Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.

Authors:  S Meri; B P Morgan; A Davies; R H Daniels; M G Olavesen; H Waldmann; P J Lachmann
Journal:  Immunology       Date:  1990-09       Impact factor: 7.397

7.  Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.

Authors:  S A Rollins; J Zhao; H Ninomiya; P J Sims
Journal:  J Immunol       Date:  1991-04-01       Impact factor: 5.422

8.  Functional properties of membrane cofactor protein of complement.

Authors:  T Seya; J P Atkinson
Journal:  Biochem J       Date:  1989-12-01       Impact factor: 3.857

9.  A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement.

Authors:  N Okada; R Harada; T Fujita; H Okada
Journal:  Int Immunol       Date:  1989       Impact factor: 4.823

10.  Antibody-independent complement activation by myelin via the classical complement pathway.

Authors:  J C Cyong; S S Witkin; B Rieger; E Barbarese; R A Good; N K Day
Journal:  J Exp Med       Date:  1982-02-01       Impact factor: 14.307

View more
  16 in total

1.  Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease.

Authors:  L B Yang; R Li; S Meri; J Rogers; Y Shen
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 2.  Membrane defence against complement lysis: the structure and biological properties of CD59.

Authors:  A Davies; P J Lachmann
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Release of intracellular calcium stores leads to retraction of membrane sheets and cell death in mature mouse oligodendrocytes.

Authors:  J A Benjamins; L Nedelkoska
Journal:  Neurochem Res       Date:  1996-04       Impact factor: 3.996

4.  Central pontine myelinolysis: historical and mechanistic considerations.

Authors:  Michael D Norenberg
Journal:  Metab Brain Dis       Date:  2010-02-25       Impact factor: 3.584

Review 5.  The complement system in central nervous system diseases.

Authors:  H Rus; F Niculescu
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

6.  p75 neurotrophin receptor expression on adult human oligodendrocytes: signaling without cell death in response to NGF.

Authors:  U Ladiwala; C Lachance; S J Simoneau; A Bhakar; P A Barker; J P Antel
Journal:  J Neurosci       Date:  1998-02-15       Impact factor: 6.167

7.  Bystander mechanism for complement-initiated early oligodendrocyte injury in neuromyelitis optica.

Authors:  Lukmanee Tradtrantip; Xiaoming Yao; Tao Su; Alex J Smith; Alan S Verkman
Journal:  Acta Neuropathol       Date:  2017-05-31       Impact factor: 17.088

8.  Clinical and immunopathologic alterations in rhesus macaques affected with globoid cell leukodystrophy.

Authors:  Juan T Borda; Xavier Alvarez; Mahesh Mohan; Marion S Ratterree; Kathrine Phillippi-Falkenstein; Andrew A Lackner; Bruce A Bunnell
Journal:  Am J Pathol       Date:  2007-12-28       Impact factor: 4.307

9.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

10.  The expression of CD59 in normal human nervous tissue.

Authors:  C Vedeler; E Ulvestad; L Bjørge; G Conti; K Williams; S Mørk; R Matre
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.